Jülg B, Goebel F D
Dept. of Infectious Diseases, Medical Policlinic, Ludwig Maximilian University Munich, Pettenkoferstr. 8a, 80336, Munich, Germany.
Infection. 2006 Oct;34(5):294-7. doi: 10.1007/s15010-006-6506-5.
Topics highlighted at the XVI International AIDS Conference in Toronto included HIV/AIDS vaccine research, entry inhibitors, integrase inhibitors, new NNRTIs and PIs, single-agent therapies, pre-exposure prophylaxis and microbicides. Beside the large scientific part, policy and funding were of great concern. Within this article we are trying to focus on topics with direct clinical relevance. This includes new epidemiological and resistance data, results from current studies investigating established and novel antiretroviral drugs and drug classes as well as new findings in therapy management and strategies.
在多伦多举行的第十六届国际艾滋病大会上突出的主题包括艾滋病毒/艾滋病疫苗研究、进入抑制剂、整合酶抑制剂、新型非核苷类逆转录酶抑制剂和蛋白酶抑制剂、单药疗法、暴露前预防和杀微生物剂。除了大量的科学内容外,政策和资金也备受关注。在本文中,我们试图聚焦于具有直接临床相关性的主题。这包括新的流行病学和耐药性数据、当前对已有的和新型抗逆转录病毒药物及药物类别进行研究的结果,以及治疗管理和策略方面的新发现。